Oxyntomodulin vs Survodutide

Oxyntomodulin is a natural gut hormone that weakly activates both GLP-1 and glucagon receptors. Survodutide was engineered to deliver that dual action with a practical half-life.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Oxyntomodulin

A natural 37-amino-acid gut hormone that activates both the GLP-1 and glucagon receptors — the template for the dual-agonist drug class.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Survodutide

A dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH).

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Oxyntomodulin	Survodutide
The key difference	Native gut dual agonist, short-lived	Engineered long-acting dual agonist
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Released from intestinal L-cells after meals, oxyntomodulin combines GLP-1-receptor effects (satiety, insulin) with glucagon-receptor effects (energy expenditure).	Modelled on oxyntomodulin, survodutide activates both the GLP-1 receptor (appetite, insulin) and the glucagon receptor (energy expenditure, hepatic fat metabolism) — the rationale for its liver-disease programme.
Status	Endogenous hormone and research tool; oxyntomodulin-based analogues are in late-stage development.	Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved.
Reported safety signals	As a short-lived native hormone, research administration has been brief; class effects follow GLP-1/glucagon biology.	Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.
A key study	Reviews oxyntomodulin as a dual GLP-1R/GCGR agonist with weight-lowering effects. (Mol Metab 2014, PMID 24749050)	Describes the discovery and preclinical pharmacology of survodutide as an oxyntomodulin-like dual agonist. (Mol Metab 2022, PMID 36356832)

WHEN TO RESEARCH WHICH

Oxyntomodulin is the physiological template; survodutide the drug-like realisation. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Oxyntomodulin] Action and therapeutic potential of oxyntomodulin — Mol Metab 2014. PMID 24749050
[Oxyntomodulin] Unraveling oxyntomodulin, GLP1’s enigmatic brother — J Endocrinol 2012. PMID 23019069
[Oxyntomodulin] Oxyntomodulin - past, present and future — Peptides 2025. PMID 40187415
[Survodutide] BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy — Mol Metab 2022. PMID 36356832
[Survodutide] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — Lancet Diabetes Endocrinol 2024. PMID 38330987
[Survodutide] A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — N Engl J Med 2024. PMID 38847460

FREQUENTLY ASKED

What is the difference between Oxyntomodulin and Survodutide?

Oxyntomodulin is a natural gut hormone that weakly activates both GLP-1 and glucagon receptors. Survodutide was engineered to deliver that dual action with a practical half-life.

What is the regulatory status of Oxyntomodulin and Survodutide?

Oxyntomodulin: Endogenous hormone and research tool; oxyntomodulin-based analogues are in late-stage development. Survodutide: Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved.

What safety signals have been reported?

Oxyntomodulin: As a short-lived native hormone, research administration has been brief; class effects follow GLP-1/glucagon biology. Survodutide: Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.

Which studies is this comparison based on?

For Oxyntomodulin: “Action and therapeutic potential of oxyntomodulin” (PMID 24749050); “Unraveling oxyntomodulin, GLP1’s enigmatic brother” (PMID 23019069); “Oxyntomodulin - past, present and future” (PMID 40187415). For Survodutide: “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy” (PMID 36356832); “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial” (PMID 38330987); “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis” (PMID 38847460).